Trial Profile
An Exploratory Study to Evaluate Weight Loss, Body Composition Changes, Food Intake and Urine Glucose Excretion in Healthy Obese Subjects Over 8 Weeks of Dosing With GSK189075, GW869682 Versus Placebo.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Sep 2023
Price :
$35
*
At a glance
- Drugs Remogliflozin etabonate (Primary) ; Sergliflozin (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 06 Apr 2009 New trial record